BRAF and melanoma: In order to understand factors influencing drug response to the single treatments, we first assessed the cell viability with an MTS assay upon treatment with dabrafenib in a panel of BRAF‐mutant melanoma cell lines that included patient‐derived xenografts (PDX) collected before treatment with vemurafenib (M026.X1.CL) and after the onset of resistance due to an acquired NRAS mutation (M026R.X1.CL; Possik et al, 2014; Kemper et al, 2016).